GNPX genprex.com: Rasio rega marang prakiraan pendapatan
Genprex, Inc. (GNPX) management is strictly focused on validating the efficacy of its oncology drugs. The forward price-to-sales ratio demonstrates current dynamics, where the level captures the present state. Looking ahead, Genprex, Inc. (GNPX) plans the global expansion of REQORSA therapy and the development of the Oncoprex ecosystem for targeted gene delivery in lung tumors, aiming to secure a dominant position in the sector.
GNPX (Genprex Inc): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Total Utang marang Modal Genprex, Inc.|GNPX - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Genprex, Inc.|GNPX - Utang agregat perusahaan|Utang marang nilai buku Genprex Inc|GNPX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Genprex|Likuiditas cepet genprex.com
- data bathi bisnis lan rasio investasi:
GNPX - Bathi perusahaan|Proyeksi bathi mangsa ngarep Genprex, Inc.|GNPX - Koefisien rega marang bathi|Prakiraan rega marang bathi Genprex, Inc|GNPX - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Genprex Inc|GNPX - Bathi operasional sadurunge potongan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Genprex|GNPX - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan genprex.com|GNPX - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Genprex, Inc.
- informasi babagan volume dodolan lan pendapatan:
Pambiji fundamental perusahaan:Genprex (GNPX)
Investors view Genprex, Inc. (GNPX) as a high-risk asset with breakthrough potential in lung cancer therapy via the ONCOPREX system. Analyzing the current forward P/S ratio on GURU.Markets reveals the relationship between market capitalization and expected sales, reflecting the degree of market optimism priced in regarding the commercialization of gene therapy and determining the sensitivity of quotes to any changes in revenue forecasts.
Pesaing wigati
Multiplikator Forward P/S ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RVMD - Rasio rega marang prakiraan pendapatan|AAPG (Ascentage Pharma Corp) - Kapitalisasi marang prakiraan pendapatan|CG Oncology, Inc. (CGON) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan URGN (urogen.com)|Rasio rega marang prakiraan pendapatan Bicara Therapeutics|PSNL: Rega forward marang dodolan|Multiplikator Forward P/S ERAS|DCTH - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|AURA: Kapitalisasi marang prakiraan pendapatan|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc)|SLS: Multiplikator Forward P/S|ACTU - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Citius Oncology, Inc.|Kapitalisasi marang prakiraan pendapatan HURA (TuHURA)|Multiplikator Forward P/S TARA|Multiplikator forward rega marang pendapatan Fate Therapeutics Inc FATE|Aadi Bioscience - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake TScan Therapeutics Inc (TCRX)|Champions Oncology Corp - Multiplikator Forward P/S|Prakiraan rega marang pendapatan XBiotech Inc. (XBIT)|cel-sci.com (CVM) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan OSTX|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Artiva - Rega mangsa ngarep marang pendapatan|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Ltd.)|verupharma.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S TPST (Tempest Therapeutics, Inc.)|XLO - Multiplikator forward rega marang pendapatan|Enochian BioSciences - Multiplikator Forward P/S|MURA - Multiplikator Forward P/S|kairospharma.com (KAPA) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan OKUR|GDTC (CytoMed Therapeutics Ltd) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Curis Corp (CRIS)|Multiplikator Forward P/S APLM|THAR - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Advanced Biomed ADVB|Rega forward marang dodolan CLDI|SBFM: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan XBIO (Xenetic Biosciences)|SLRX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Kitov Pharma|Multiplikator forward rega marang pendapatan AONC|Multiplikator Forward P/S beigene.com|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|ELEV (elevationoncology.com) - Rega forward marang dodolan|Multiplikator Forward P/S ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Notable Labs, Ltd. - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Viracta Therapeutics (VIRX)|MOR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NAYA Biosciences Inc (NAYA)|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
